Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Provided By GlobeNewswire
Last update: Nov 13, 2024
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 4:00 p.m. GMT.
Read more at globenewswire.com
